RPL Peptide

Official Technical Documentation

Retatrutide Technical Manual¶

Field	Value
Document Title	Retatrutide — Complete Technical Documentation
Document ID	RPL-TM-RET-001
Document Type	Complete Technical Documentation Manual
Publisher	RPL Peptide (Qingdao RPL Biotechnology Co., Ltd.)
Version	1.0
Revision Date	July 2026
Status	Current
Intended Audience	Research laboratories, procurement professionals, quality assurance teams, biotechnology organizations, and scientific researchers
Scope	This manual covers the complete technical documentation for Retatrutide (CAS: 2381089-83-2), a synthetic 39-amino-acid triple receptor agonist peptide targeting GLP-1R, GIPR, and GCGR. Includes product specifications, analytical methods, safety data, handling protocols, quality standards, and supporting reference materials for laboratory research use.
Keywords	Retatrutide, GLP-1R/GIPR/GCGR triple agonist, triple incretin agonist, glucagon receptor, metabolic research peptide, synthetic peptide, GLP-1 receptor agonist, GIP receptor agonist, GCGR agonist, peptide research, laboratory reagent
How to Cite This Document	RPL Peptide. (2026). Retatrutide Technical Manual (Version 1.0). RPL Peptide Official Technical Documentation. https://rplpeptides.com

Table of Contents¶

Chapter	Title
1	Technical Data Sheet
2	Certificates of Analysis
3	Product Specifications
4	Safety Data Sheet
5	HPLC Library
6	Mass Spectra Library
7	Storage Guide
8	Solubility Guide
9	Reconstitution Guide
10	Stability Guide
11	Analytical Methods
12	Quality Standards
13	White Paper
14	Technical Bulletin
15	Application Notes
16	FAQ Library
17	Peptide Glossary
18	Documentation Policy

Chapter 1: Technical Data Sheet¶

Product Overview¶

Retatrutide is a synthetic 39-amino-acid triple receptor agonist peptide engineered to simultaneously interact with three distinct receptor systems: glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This multi-agonist architecture differentiates Retatrutide from earlier incretin-focused compounds by enabling researchers to examine how multiple hormonal pathways influence metabolic regulation simultaneously.

Product Specifications¶

Parameter	Specification
Product Name	Retatrutide
CAS Number	2381089-83-2
Synonyms	Triple GLP-1R/GIPR/GCGR Receptor Agonist Peptide
Amino Acid Count	39 Amino Acids
Molecular Weight	~4,900 Da
Peptide Type	Synthetic Modified Peptide
Classification	Triple Incretin/Glucagon Receptor Agonist
Appearance	White to Off-White Lyophilized Powder
Purity (HPLC)	≥99.0%
Peptide Content	70–90%
Water Content (KF)	<5%
Endotoxin	<5 EU/mg
Solubility	Soluble in water, PBS, saline
pH (1% Solution)	4.0–6.5
Storage (Lyophilized)	-20°C (2+ years)
Storage (4°C)	12 months
Reconstituted Stability	2–8°C for 30 days
Package Sizes	10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg vial
Certification	COA, HPLC, LC-MS

Receptor Targets¶

Receptor	Type	Research Significance
GLP-1R	Glucagon-like peptide-1 receptor	Incretin signaling, insulin secretion
GIPR	Glucose-dependent insulinotropic polypeptide receptor	Nutrient-responsive signaling
GCGR	Glucagon receptor	Energy metabolism, glucose homeostasis

Quality Assurance¶

Each batch is tested using validated analytical methods: - HPLC purity analysis at 214 nm - LC-MS molecular weight confirmation (±0.5 Da) - UPLC chromatographic profiling - Water content by Karl Fischer (KF) - Endotoxin testing (LAL method) - Batch-specific Certificate of Analysis (COA) - Third-party analytical validation available upon request

Reconstitution Protocol¶

Equilibrate vial to room temperature (15–25°C).
Briefly centrifuge to collect powder at vial bottom.
Add bacteriostatic water (0.9% benzyl alcohol) against inner wall.
Swirl gently — DO NOT vortex or shake vigorously.
Clear solution = complete reconstitution.
Recommended concentration: 1–5 mg/mL.

Regulatory & Disclaimer¶

This product is for laboratory research use only. NOT for human or veterinary consumption, medical treatment, diagnosis, or therapeutic application. All research must comply with applicable regulations.

Chapter 2: Certificates of Analysis¶

⚠️ This document is a template for reference only. Batch-specific Certificates of Analysis (COA) with real analytical data are issued per production batch. To request a specific COA, please contact RPL Peptide staff at www.rplpeptides.com.

Batch Information¶

Field	Details
Product Name	Retatrutide (GLP-1R/GIPR/GCGR Triple Agonist)
CAS Number	2381089-83-2
Batch Number	[Batch Number]
Manufacturing Date	[YYYY-MM-DD]
Retest Date	[YYYY-MM-DD]
Certificate Issue Date	[YYYY-MM-DD]
Lot Quantity	[Quantity] vials
Package Size	[mg] per vial
Manufacturer	RPL Peptide (Qingdao RPL Biotechnology Co., Ltd.)

Analytical Results¶

Test	Method	Specification	Result
Appearance	Visual Inspection	White to off-white lyophilized powder	[Result]
Identification (LC-MS)	LC-MS	Consistent with reference standard (±0.5 Da)	[Result]
Purity (HPLC)	HPLC (214 nm)	≥99.0%	[Result]
Peptide Content	UV/Amino Acid Analysis	70–90%	[Result]
Water Content (KF)	Karl Fischer	<5.0%	[Result]
Endotoxin (LAL)	LAL Method	<5 EU/mg	[Result]
pH (1% Solution)	pH Meter	4.0–6.5	[Result]

Chromatographic & LC-MS Data¶

Parameter	Value
Retention Time	[Minutes]
Main Peak Purity	[%]
Calculated Molecular Weight	~4,900 Da
Observed Molecular Weight	[Da]
Mass Accuracy	±0.5 Da

Quality Control Status¶

Review Item	Status
QC Review	[Approved / Rejected]
Reviewed By	[Name]
Release Status	[Released / On Hold]

Notes¶

This certificate is generated for each batch and is part of the full traceability documentation.
Original analytical data and chromatograms are archived and available upon request.
Third-party analytical validation available upon request.

Authorized Signature¶

[QC Manager Name] Quality Control Department RPL Peptide

Chapter 3: Product Specifications¶

General Information¶

Specification	Detail
Product Name	Retatrutide
CAS Number	2381089-83-2
Molecular Weight	~4,900 Da
Amino Acid Count	39
Peptide Type	Synthetic triple receptor agonist
Target Receptors	GLP-1R, GIPR, GCGR
Research Category	Metabolic Research Peptides

Physical Properties¶

Property	Specification
Appearance	White to off-white lyophilized powder
Odor	Odorless or slight acetic
pH (1% Solution)	4.0–6.5
Solubility in Water	Soluble (≥10 mg/mL)
Solubility in PBS	Soluble (≥10 mg/mL)
Solubility in Saline	Soluble (≥10 mg/mL)
Melting Point	Decomposes >200°C
Hygroscopicity	Hygroscopic — protect from moisture

Purity & Quality Specifications¶

Parameter	Specification	Analytical Method
HPLC Purity	≥99.0%	HPLC at 214 nm
Peptide Content	70–90%	UV / Amino Acid Analysis
Water Content	<5.0%	Karl Fischer Titration
Endotoxin	<5 EU/mg	LAL Method
Counterion (TFA)	<1.0%	HPLC / Ion Chromatography
Identity	±0.5 Da	LC-MS

Packaging Specifications¶

Parameter	Standard	Custom
Package Sizes	10, 15, 20, 30, 40, 50, 60 mg	Upon request
Vial Material	Type I borosilicate glass	Custom labeling available
Packaging Quantity	10 vials per box (standard)	Bulk packaging available

Storage & Shipping¶

Condition	Duration
Lyophilized at -20°C	2+ years
Lyophilized at 2–8°C	12 months
UN Number	Not regulated
Transport	Ambient, 2–8°C cold-chain, or -20°C dry ice

Regulatory Classification¶

GHS Classification: Not classified as hazardous in solid form under normal handling conditions
Intended Use: Laboratory research use only

Chapter 4: Safety Data Sheet¶

SECTION 1: Identification¶

Field	Detail
Product Name	Retatrutide (Lyophilized Research Peptide)
Chemical Family	Synthetic Peptide / Biochemical Research Reagent
CAS Number	2381089-83-2
Supplier	RPL Peptide (Qingdao RPL Biotechnology Co., Ltd.)
Address	Qingdao, Shandong Province, China
Website	www.rplpeptides.com
Intended Use	Laboratory research use only

SECTION 2: Hazards Identification¶

GHS Classification: Not classified as hazardous in solid form under normal handling conditions.

Potential Hazards: - Dust/aerosol may cause respiratory irritation if inhaled - May cause eye irritation upon direct contact - Avoid ingestion - Lyophilized peptide may be hygroscopic

SECTION 3: Composition / Information on Ingredients¶

Component	Details
Active Ingredient	Retatrutide (≥99.0% pure)
Counterion	TFA (CAS 76-05-1) — residual (<1%)
Water	Residual moisture (<5%)
Excipients	Mannitol or sucrose may be present (variable)

SECTION 4: First-Aid Measures¶

Route	Procedure
Inhalation	Move to fresh air. Seek medical attention if breathing difficulty persists.
Skin Contact	Wash with soap and water for 15 minutes.
Eye Contact	Rinse with water for 15 minutes. Seek medical attention if irritation persists.
Ingestion	Rinse mouth. Do NOT induce vomiting. Seek immediate medical attention.

SECTION 5: Fire-Fighting Measures¶

Extinguishing Media: Water spray, dry chemical, CO₂, alcohol-resistant foam. Thermal Decomposition: CO, CO₂, NOx, HF.

SECTION 6–11: Standard Safety Information¶

(Refer to the Tirzepatide SDS for full 16-section GHS structure — generic lyophilized peptide safety profile applies.)

SECTION 14: Transport Information¶

Classification	Detail
UN Number	Not regulated
Hazard Class	Not classified as hazardous goods

This SDS is for informational purposes. Users should conduct their own risk assessment.

Chapter 5: HPLC Library¶

Analytical Method¶

Parameter	Specification
Method	RP-HPLC
Detection Wavelength	214 nm
Column	C18, 4.6 × 250 mm, 5 μm
Mobile Phase A	0.1% TFA in Water
Mobile Phase B	0.1% TFA in Acetonitrile
Gradient	Linear 20–60% B over 30 min
Flow Rate	1.0 mL/min
Injection Volume	20 μL
Column Temperature	25°C
Run Time	40 minutes

Acceptance Criteria¶

Parameter	Limit
Main Peak Purity	≥99.0%
Single Impurity	≤0.5%
Total Impurities	≤1.0%
Theoretical Plates	≥10,000
Tailing Factor	0.8–1.5

Batch-Specific Data¶

Batch Number	Purity (%)	Retention Time (min)
[Batch-001]	—	—

HPLC analysis performed on every batch prior to release
Chromatograms archived and available upon request

Chapter 6: Mass Spectra Library¶

Analytical Method¶

Parameter	Specification
Method	LC-MS
Ionization	ESI, Positive Mode
Mass Analyzer	Q-TOF
Scan Range	m/z 500–2500
Mass Accuracy	±0.5 Da

Expected Mass Data¶

Parameter	Value
Calculated Average Mass	~4,900 Da
Monoisotopic Mass	[M+H]⁺ = ~4,901 Da
Charge State Series	[M+3H]³⁺ to [M+7H]⁷⁺

Acceptance Criteria¶

Parameter	Limit
Mass Accuracy	±0.5 Da of calculated value
Signal-to-Noise	≥10:1

Batch-Specific Data¶

Batch Number	Observed Mass (Da)	Mass Accuracy (Da)
[Batch-001]	—	—

Chapter 7: Storage Guide¶

Recommended Storage Conditions¶

Condition	Duration	Container
2–8°C (Refrigerated)	Up to 12 months	Sealed, original vial
-20°C (Freezer)	2+ years	Sealed, original vial
Room Temperature (15–25°C)	Up to 30 days	Sealed, desiccated
-80°C (Ultra-Low)	5+ years	Sealed, original vial

Reconstituted Product Storage¶

Condition	Duration
2–8°C (Refrigerated)	Up to 30 days
Room Temperature	Up to 7 days
-20°C (Aliquoted)	Up to 6 months

Critical Storage Rules¶

Keep sealed — Protect from atmospheric moisture
Protect from light — Store in original packaging
Avoid freeze-thaw — Aliquot for single-use
Temperature stability — Avoid prolonged exposure above 25°C

Storage Troubleshooting¶

Issue	Possible Cause	Solution
Cake collapse	Moisture absorption	Discard; check seal
Discoloration	Light exposure	Discard; protect from light
Insoluble after reconstitution	Improper storage	Verify storage history

Chapter 8: Solubility Guide¶

Solubility Profile¶

Solvent	Solubility	Notes
Water	≥10 mg/mL	Clear solution
PBS	≥10 mg/mL	Biocompatible
0.9% Saline	≥10 mg/mL	Suitable for research
Bacteriostatic Water (0.9% BA)	≥10 mg/mL	Recommended for reconstitution
Buffers (pH 5–7)	≥10 mg/mL	Optimal pH range

Recommended Reconstitution Solvents¶

Primary: Bacteriostatic Water (0.9% Benzyl Alcohol) - Recommended concentration: 1–5 mg/mL - Stable at 2–8°C for up to 30 days

Alternatives: Sterile WFI, PBS, 0.9% Saline

Step-by-Step Protocol¶

Equilibrate vial to room temperature (10–15 min)
Briefly centrifuge (3,000–5,000 rpm, 30 sec)
Add solvent against inner wall
Swirl gently — DO NOT vortex
Verify clear solution

Concentration Guidelines¶

Application	Recommended Concentration
General Research	1–5 mg/mL
In Vitro Assays	0.1–1 mg/mL (diluted)

Chapter 9: Reconstitution Guide¶

Materials Required¶

Lyophilized Retatrutide vial
Bacteriostatic water (0.9% benzyl alcohol) or sterile water
Alcohol swabs (70% isopropyl)
Sterile syringe and needle (1–3 mL)
Microcentrifuge (recommended)
PPE (gloves, goggles, lab coat)

Standard Reconstitution Protocol¶

Step 1: Preparation¶

Equilibrate vial to room temperature (10–15 min)

Step 2: Centrifuge¶

Brief spin at 3,000–5,000 rpm for 30 seconds

Step 3: Vial Preparation¶

Swab rubber stopper with alcohol; allow evaporation

Step 4: Solvent Addition¶

Inject solvent against inner glass wall — NOT directly onto powder

Step 5: Dissolution¶

Gently swirl until fully dissolved
DO NOT vortex or shake vigorously

Step 6: Inspection¶

Clear solution = complete reconstitution

Reconstitution Volume Table¶

Vial Size	1 mg/mL	2 mg/mL	5 mg/mL
10 mg	10 mL	5 mL	2 mL
20 mg	20 mL	10 mL	4 mL
30 mg	30 mL	15 mL	6 mL
50 mg	50 mL	25 mL	10 mL
60 mg	60 mL	30 mL	12 mL

Post-Reconstitution Handling¶

2–8°C: up to 30 days
Aliquot to avoid freeze-thaw
Label vial with name, concentration, date, batch

Chapter 10: Stability Guide¶

Stability Summary¶

Form	Condition	Duration
Lyophilized	-20°C	2+ years
Lyophilized	2–8°C	12 months
Lyophilized	25°C	30 days
Reconstituted	2–8°C	30 days
Reconstituted	25°C	7 days

Freeze-Thaw Stability¶

Cycles	Purity Retention
1	≥99%
3	≥98%
5	≥97%

Aliquot for single-use; avoid repeated freeze-thaw.

Degradation Pathways¶

Pathway	Risk	Mitigation
Hydrolysis	Medium	Keep dry
Oxidation	Low-Medium	Inert atmosphere
Aggregation	Low	Gentle handling

Chapter 11: Analytical Methods¶

Method Overview¶

Method	Purpose	Specification
HPLC	Purity Analysis	≥99.0%
LC-MS	Identity Confirmation	±0.5 Da
Karl Fischer	Water Content	<5.0%
LAL Test	Endotoxin	<5 EU/mg

1. HPLC Method¶

Parameter	Specification
Column	C18, 4.6 × 250 mm, 5 μm
Detection	UV at 214 nm
Mobile Phase	0.1% TFA in H₂O / ACN
Gradient	20–60% B, 30 min
Flow Rate	1.0 mL/min

2. LC-MS Method¶

Parameter	Specification
Ionization	ESI, Positive Mode
Mass Accuracy	±0.5 Da
Scan Range	m/z 500–2500

3. Karl Fischer (KF)¶

Coulometric titration
Acceptance: <5.0%

4. LAL Endotoxin¶

Kinetic Turbidimetric
Acceptance: <5 EU/mg

Document Control¶

Version	Date	Author
1.0	July 2026	RPL Peptide Quality

Chapter 12: Quality Standards¶

Quality Policy¶

RPL Peptide is committed to supplying research-grade peptides that meet defined purity and quality specifications through standardized manufacturing, analytical verification, batch traceability, and continuous improvement.

Manufacturing Standards¶

Standard	Description
Synthesis	Solid-Phase Peptide Synthesis (SPPS)
Reproducibility	Standardized reaction conditions
Purification	Preparative HPLC
Lyophilization	Controlled conditions
Packaging	Clean environment

Analytical Specifications¶

Parameter	Standard	Method
Purity	≥99.0%	HPLC at 214 nm
Identity	±0.5 Da	LC-MS
Water Content	<5.0%	Karl Fischer
Endotoxin	<5 EU/mg	LAL Test

Batch Traceability¶

Unique lot number linking: manufacturing records → analytical data → QC review → COA → shipment.

Release Criteria (ALL must pass)¶

HPLC purity ≥99.0%
LC-MS identity confirmed
Water <5.0%
Endotoxin <5 EU/mg
Documentation complete

Chapter 13: White Paper¶

Abstract¶

This white paper provides a comprehensive overview of Retatrutide, a research-grade Synthetic Modified Peptide manufactured by RPL Peptide. It covers the biochemical background, research applications, analytical characterization, and quality considerations relevant to laboratory research use.

1. Introduction¶

Retatrutide is a synthetic Synthetic Modified Peptide supplied exclusively for laboratory research and analytical applications. This compound represents an important tool for investigating cellular signaling pathways, metabolic regulation, and physiological processes in controlled experimental settings.

The development and characterization of high-quality research compounds require rigorous attention to synthesis, purification, analytical characterization, and quality control. This white paper outlines the key scientific principles, manufacturing approach, and quality framework applied to Retatrutide.

2. Scientific Background¶

2.1 Biochemical Context¶

Synthetic Modified Peptide compounds serve as valuable research tools for investigating molecular mechanisms in cell biology and biochemistry. Their application spans studies of receptor pharmacology, enzyme kinetics, signal transduction, and metabolic pathway analysis.

2.2 Research Applications¶

The primary research applications for Retatrutide include: - In vitro receptor binding and functional assays — Determining potency, efficacy, and selectivity - Cell-based functional studies — Investigating downstream signaling pathway activation - Comparative pharmacology — Evaluating structure-activity relationships - Metabolic and biochemical pathway analysis — Understanding physiological effects at the molecular level

2.3 Structural Considerations¶

As a synthetic research compound, Retatrutide is produced through controlled chemical synthesis enabling precise control over molecular structure, purity profile, and batch-to-batch consistency.

3. Quality by Design¶

QbD Element	Implementation
Raw Material Qualification	All raw materials tested to established specifications before use
Process Validation	Manufacturing process parameters established and monitored
In-Process Controls	Key quality attributes monitored during synthesis and purification
Final Product Testing	Comprehensive multi-method analysis per batch
Stability Monitoring	Ongoing stability studies to establish and confirm shelf life
Continuous Improvement	Regular review of quality metrics and process optimization

4. Documentation and Support¶

Each shipment of Retatrutide includes: 1. Certificate of Analysis (COA) — Batch-specific analytical results 2. HPLC Chromatogram — Purity profile with peak identification 3. Mass Spectrometry Data — Confirmed molecular identity 4. Safety Data Sheet (SDS) — Handling information 5. Product Specification Document — Detailed quality parameters

5. Regulatory and Ethical Considerations¶

Retatrutide is manufactured and supplied exclusively for laboratory research use. Not for human or veterinary administration, therapeutic use, or diagnostic applications.

References¶

RPL Peptide Quality Manual (Document QM-001)
ICH Q2(R1) Validation of Analytical Procedures
ICH Q6B Specifications for Biotechnological/Biological Products

Chapter 14: Technical Bulletin¶

Bulletin No.: RPL-TB-RET-001 Date: July 2026 Subject: Handling and Analytical Guidance for Retatrutide Research Material

1. Handling Recommendations¶

Area	Recommendation
Equilibration	10–15 minutes at room temperature
Centrifugation	Strongly recommended (3,000–5,000 rpm, 30 sec)
Solvent Addition	Against inner wall only
Concentration	1–5 mg/mL (optimal)

2. Storage¶

Condition	Duration
-20°C (Lyophilized)	2+ years
2–8°C (Lyophilized)	12 months
2–8°C (Reconstituted)	30 days

3. Quality Advisory¶

All retatrutide batches released from RPL Peptide meet: - ✅ HPLC Purity ≥99.0% - ✅ LC-MS Identity Confirmed (±0.5 Da) - ✅ Endotoxin <5 EU/mg - ✅ Full Batch Traceability - ✅ Certificate of Analysis Included

4. Contact¶

RPL Peptide Quality Department Website: www.rplpeptides.com

Next review: January 2027

Chapter 15: Application Notes¶

1. Introduction¶

This application note provides standardized protocols for using Retatrutide in common in vitro research applications. These protocols are intended as starting points; optimization for specific cell types and experimental conditions may be required.

2. Preparation of Stock Solutions¶

2.1 Materials Required¶

Retatrutide (lyophilized powder)
Sterile water for injection (WFI) or PBS (pH 7.4)
Low-binding microcentrifuge tubes
Analytical balance (precision ±0.01 mg)
pH meter (calibrated)

2.2 Stock Solution Preparation¶

Step	Action	Notes
1	Equilibrate lyophilized product to room temperature (15–30 min)	Prevents moisture condensation
2	Reconstitute in appropriate volume of WFI or PBS	Calculate for target stock concentration
3	Gently swirl or invert to dissolve	Do NOT vortex — causes aggregation
4	Visually inspect for complete dissolution	Clear, no particulates
5	Aliquot into single-use tubes	Avoid repeated freeze-thaw
6	Store at -20°C	Stable up to 6 months

2.3 Concentration Calculation¶

Stock Concentration (M) = Mass (mg) / [Molecular Weight (g/mol) × Volume (L)]

3. Cell-Based Functional Assay Protocol¶

3.1 Materials Required¶

Retatrutide (reconstituted stock solution)
Appropriate cell line expressing target receptor/pathway
Cell culture medium (serum-free for treatments)
96-well or 384-well culture plates
Assay detection kit
Microplate reader
Positive and vehicle controls

3.2 Cell Preparation¶

Step	Action	Duration
1	Culture cells to 70–80% confluence	2–3 days
2	Serum-starve overnight before assay	16–18 h
3	Harvest and count cells	5 min
4	Resuspend in assay buffer	—
5	Seed at 5,000–10,000 cells/well	15 min
6	Equilibrate	30 min

3.3 Compound Treatment¶

Step	Action	Detail
1	Prepare serial dilutions of Retatrutide	10⁻¹² to 10⁻⁶ M, 10-fold steps
2	Add 50 µL per well	Triplicate per concentration
3	Incubate for 30 min	Optimize per assay
4	Stop reaction	Per kit instructions
5	Measure endpoint	Within specified time window

3.4 Data Analysis¶

Parameter	Software	Model
EC₅₀ / IC₅₀	GraphPad Prism	Log(agonist) vs. response — variable slope
Statistics	GraphPad Prism	ANOVA with post-hoc test
Z' factor	Manual	Z' = 1 − [3(SD₊ + SD₋) /

3.5 Quality Control Criteria¶

Parameter	Acceptance
Z' factor	> 0.5 (acceptable); > 0.7 (excellent)
Positive control EC₅₀	Within ±0.5 log of historical mean
Vehicle control	No significant signal above baseline
CV (triplicates)	< 15%

4. Troubleshooting¶

Problem	Cause	Solution
High baseline	Vehicle interference	Reduce DMSO ≤0.1%; use PBS vehicle
No dose-response	Compound degradation	Verify storage; use fresh aliquot
	Incubation too short	Extend 30→60 min
High variability	Poor cell seeding	Pre-coat plates with poly-D-lysine
EC₅₀ shift	Serum interference	Ensure complete serum removal

5. Notes and Considerations¶

Include positive and negative controls in every experiment
Use low-binding tubes and tips
Prepare fresh stock or use single-use aliquots
Triplicate, repeat ≥3 independent times
Record batch numbers for compound, cells, and reagents

Chapter 16: FAQ Library¶

Product Information¶

1. What is Retatrutide?¶

Retatrutide is a Synthetic Modified Peptide manufactured by RPL Peptide as a research-grade material for laboratory use only.

2. What is the molecular weight and CAS number?¶

Refer to the Technical Data Sheet for the most current molecular weight and CAS number information for this product.

3. What purity does RPL Peptide supply?¶

RPL Peptide supplies Retatrutide at ≥98% as determined by HPLC analysis at 214 nm. Batch-specific purity is provided on the Certificate of Analysis.

Quality and Documentation¶

4. What documentation is included with each shipment?¶

Each shipment includes a Certificate of Analysis (COA), HPLC chromatogram, LC-MS data, and Safety Data Sheet (SDS).

5. Does RPL Peptide provide batch-specific data?¶

Yes. Each batch is individually tested and documented with batch-specific COA, HPLC chromatogram, and LC-MS data.

6. How does RPL Peptide ensure batch-to-batch consistency?¶

RPL Peptide maintains strict quality control with defined specifications for each quality parameter. All batches must meet the same release criteria, and deviations are investigated through the CAPA system.

7. What is the difference between peptide content and HPLC purity?¶

HPLC purity measures the percentage of the target compound peak area relative to all detected peaks. Peptide content measures the actual compound mass relative to the total lyophilized weight (which includes water, residual TFA, and counterions).

Handling and Usage¶

8. How should lyophilized Retatrutide be stored?¶

Store at -20°C, protected from light and moisture. Short-term storage at 2–8°C is acceptable for up to 12 months. Do not store at room temperature for extended periods.

9. What solvent should be used for reconstitution?¶

Sterile water-for-injection (WFI), PBS (pH 7.4), or 0.9% saline are recommended. The choice depends on the specific experimental requirements.

10. How long can reconstituted product be stored?¶

Reconstituted product is stable for up to 30 days at 2–8°C or up to 6 months at -20°C when properly aliquoted.

11. Can the product be vortexed?¶

No. Vortexing can cause aggregation. Gently swirl or invert to dissolve.

12. How many freeze-thaw cycles are acceptable?¶

We recommend no more than 3 freeze-thaw cycles. Aliquot into single-use portions to avoid repeated freeze-thaw.

13. What if the product does not dissolve completely?¶

(1) Allow more time — some compounds need 15–30 min. (2) Gently warm to 25°C. (3) Add 0.1% DMSO or acetic acid if compatible with downstream application.

14. Recommended concentration for cell-based assays?¶

Typical working concentrations: 1 nM to 10 µM. A full dose-response curve (8–10 points, half-log dilutions) is recommended.

Technical¶

15. How does Retatrutide compare to other compounds in its class?¶

As a Synthetic Modified Peptide |, Retatrutide has specific structural and functional characteristics that distinguish it. For comparative data, contact RPL Peptide's technical support.

16. Key analytical methods used?¶

HPLC (purity and impurity profile), LC-MS (identity confirmation), amino acid analysis (if applicable), water content (Karl Fischer), endotoxin (LAL assay).

17. How to avoid aggregation during experiments?¶

(1) Avoid vortexing. (2) Filter buffers (0.22 µm). (3) Keep stock on ice. (4) Use low-binding plasticware. (5) Add compound to buffer, not buffer to compound.

18. Can Retatrutide be used in animal studies?¶

For laboratory research use only. In vivo use requires IACUC approval and applicable regulatory compliance.

19. Shipping conditions?¶

Standard: dry ice or ice packs depending on product stability profile. All shipments include temperature monitoring indicators.

20. Where to find more information?¶

Additional information in the Technical Data Sheet, White Paper, and Application Notes. For specific inquiries: www.rplpeptides.com.

Chapter 17: Peptide Glossary¶

A¶

Amino Acid Analysis (AAA) — A method for determining the amino acid composition of a peptide by complete hydrolysis followed by chromatographic separation and quantification.

Amidation — A C-terminal modification where the carboxyl group is converted to an amide (-CONH₂), often improving stability and bioactivity.

B¶

Batch (Lot) — A specific quantity of material produced in a single manufacturing run under consistent conditions.

Bioassay — A method for determining the biological activity of a compound using living cells or organisms.

C¶

Certificate of Analysis (COA) — An official document listing the analytical results for a specific batch, including test parameters, specifications, and measured values.

C18 Column — The most common reversed-phase HPLC column, featuring octadecyl (C18) bonded silica for peptide separation.

Counterion — An ion of opposite charge associated with the peptide (commonly TFA⁻ or acetate⁻) that affects the total mass and solubility properties.

D¶

Deletion Sequence — An impurity where one or more amino acids are missing from the target sequence due to incomplete coupling during SPPS.

DMSO (Dimethyl Sulfoxide) — A polar aprotic solvent commonly used to dissolve hydrophobic compounds for cell-based assays. Use at ≤0.1% final concentration to avoid cytotoxicity.

E¶

Endotoxin — Lipopolysaccharide (LPS) components from Gram-negative bacterial cell walls. Measured by LAL (Limulus Amebocyte Lysate) assay to ensure safety.

ESI (Electrospray Ionization) — A soft ionization technique for mass spectrometry that produces multiply charged ions from solution-phase samples.

F¶

Fmoc Chemistry — A synthesis strategy using 9-fluorenylmethoxycarbonyl (Fmoc) as the temporary N-terminal protecting group in SPPS.

Freeze-Thaw Cycle — The process of freezing and thawing a sample. Repeated cycles can cause peptide degradation and aggregation.

G¶

GHS (Globally Harmonized System) — An international system for classifying and labeling chemicals based on their hazards.

Gradient (HPLC) — A solvent programming method where the mobile phase composition changes over time to achieve separation.

H¶

HPLC (High-Performance Liquid Chromatography) — A chromatographic technique used to separate, identify, and quantify components in a mixture.

Half-Life Extension — Strategies (PEGylation, fusion proteins, etc.) used to prolong the circulating half-life of peptides and proteins.

I¶

Impurity Profile — The complete characterization of all substances other than the target peptide in a sample.

Incretin — A hormone that stimulates insulin secretion in response to nutrient intake. GIP and GLP-1 are the primary incretin hormones.

K¶

Karl Fischer Titration — A method for determining water content in samples using coulometric or volumetric titration.

L¶

LC-MS (Liquid Chromatography-Mass Spectrometry) — A hyphenated technique combining HPLC separation with mass spectrometric detection.

Lyophilization — A freeze-drying process that removes water from frozen material under vacuum, producing a stable powder with extended shelf life.

M¶

Mass Accuracy — The difference between measured and calculated mass, typically expressed in Da or ppm.

MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight) — A mass spectrometry technique for peptide and protein analysis.

Monoisotopic Mass — The mass calculated using the most abundant isotope of each element.

N¶

Ninhydrin Test — A colorimetric test for free amino groups, used in SPPS to monitor coupling efficiency (Kaiser test).

O¶

Oxidation — A degradation pathway where amino acid side chains (Met, Cys, Trp) react with oxygen.

Orthogonal Protection — A protection strategy using two or more independently removable protecting groups.

P¶

Peptide Bond — An amide bond formed between the carboxyl group of one amino acid and the amino group of another.

Peptide Content — The percentage of the desired peptide in relation to all peptide-related components. Determined by HPLC or AAA.

pI (Isoelectric Point) — The pH at which a peptide has no net electrical charge, affecting solubility and purification behavior.

R¶

Reconstitution — The process of dissolving lyophilized peptide in a suitable solvent for research use.

Reversed-Phase HPLC — The most common HPLC mode for peptide analysis, using a non-polar stationary phase (C18) and polar mobile phases (water/acetonitrile with TFA).

RP-HPLC (Reversed-Phase High-Performance Liquid Chromatography) — The standard method for peptide purity analysis and preparative purification.

S¶

SPPS (Solid-Phase Peptide Synthesis) — A method for chemical synthesis of peptides where amino acids are sequentially coupled to a solid resin support.

Sequence (Amino Acid Sequence) — The linear order of amino acids in a peptide, which determines its three-dimensional structure and biological function.

T¶

TFA (Trifluoroacetic Acid) — A strong acid commonly used as an ion-pairing agent in HPLC mobile phases and present as a residual counterion in lyophilized peptides.

Truncation — An impurity resulting from incomplete chain assembly during synthesis, producing shorter peptide fragments.

U¶

UPLC (Ultra-Performance Liquid Chromatography) — A high-resolution variant of HPLC using sub-2 µm particle columns for faster, more efficient separations.

V¶

Validation (Method) — The process of demonstrating that an analytical method is suitable for its intended purpose, as defined by ICH Q2(R1).

W¶

Water Content — The percentage of water in a lyophilized peptide product, measured by Karl Fischer titration. Typically <5% for stable products.

Z¶

Z' Factor — A statistical measure of assay quality in high-throughput screening.

Chapter 18: Documentation Policy¶

Policy No.: RPL-DP-001 Effective Date: July 2026 Version: 1.0

1. Purpose¶

This policy defines the structure, content standards, revision control, and distribution guidelines for the RPL Peptide Official Technical Documentation series.

2. Scope¶

All official technical documents: Technical Data Sheets, COA, Product Specifications, SDS, HPLC Library, Mass Spectra Library, Storage/Solubility/Reconstitution/Stability Guides, Analytical Methods, Quality Standards, White Papers, Technical Bulletins, Application Notes, FAQ Library, Peptide Glossary, Documentation Policy.

3. Document Structure¶

RPL Peptide / Official Technical Documentation / [Document Type]

Format: X.Y (major.minor). Review annually.

5. Distribution¶

Public: Technical Data Sheets, Guides, White Papers, Application Notes, FAQ. Restricted: COA (per batch with shipment).

Version	Date	Author	Changes
1.0	July 2026	RPL Peptide Quality	Initial release

Official Technical Documentation

rplpeptides.com